首页> 外文期刊>Biomarkers in Cancer >BMI1: A Biomarker of Hematologic Malignancies:
【24h】

BMI1: A Biomarker of Hematologic Malignancies:

机译:BMI1:血液系统恶性肿瘤的生物标志物:

获取原文
       

摘要

BMI1 oncogene is a catalytic member of epigenetic repressor polycomb group proteins. It plays a critical role in the regulation of gene expression pattern and consequently several cellular processes during development, including cell cycle progression, senescence, aging, apoptosis, angiogenesis, and importantly self-renewal of adult stem cells of several lineages. Preponderance of evidences indicates that deregulated expression of PcG protein BMI1 is associated with several human malignancies, cancer stem cell maintenance, and propagation. Importantly, overexpression of BMI1 correlates with therapy failure in cancer patients and tumor relapse. This review discusses the diverse mode of BMI1 regulation at transcriptional, posttranscriptional, and posttranslational levels as well as at various critical signaling pathways regulated by BMI1 activity. Furthermore, this review highlights the role of BMI1 as a biomarker and therapeutic target for several subtypes of hematologic malignancies and the importance to target this biomarker for therapeutic applications.
机译:BMI1癌基因是表观遗传阻遏物多梳基团蛋白的催化成员。它在调节基因表达模式以及因此在发育过程中的几个细胞过程中起着至关重要的作用,包括细胞周期进程,衰老,衰老,凋亡,血管生成,以及重要的是几个家族的成年干细胞自我更新。大量证据表明,PcG蛋白BMI1的表达失调与几种人类恶性肿瘤,癌症干细胞维持和繁殖有关。重要的是,BMI1的过表达与癌症患者的治疗失败和肿瘤复发相关。这篇综述讨论了在转录,转录后和翻译后水平以及在由BMI1活性调节的各种关键信号通路中BMI1调节的多种模式。此外,本综述强调了BMI1作为血液恶性肿瘤的几种亚型的生物标志物和治疗靶标的作用,以及针对该生物标志物治疗应用的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号